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Increased transforming growth factor-β (TGF-β) expression and epidermal growth factor receptor (EGFR) ampliﬁcation
accompanytheemergenceofhighlyaggressivehumancarcinomas.Cooperativesignalingbetweenthesetwogrowthfactor/receptor
systems promotes cell migration and synthesis of stromal remodeling factors (i.e., proteases, protease inhibitors) that, in turn,
regulate tumor invasion, neo-angiogenesis and inﬂammation. ranscript proﬁling of transformed human cells revealed that genes
encoding wound healing, matrix remodeling and cell cycle proteins (i.e., the “tissue repair” transcriptome) are signiﬁcantly up-
regulatedearlyaftergrowthfactorstimulation.Themajorinhibitorofplasmingeneration,plasminogenactivatorinhibitor-1(PAI-
1), is among the most highly induced transcripts during the phenotypic transition initiated by TGF-β maximal expression requires
EGFR signaling. PAI-1 induction occurs early in the progression of incipient epidermal squamous cell carcinoma (SCC) and is
a signiﬁcant indicator of poor prognosis in epithelial malignancies. Mouse modeling and molecular genetic analysis of complex
systemsindicatesthatPAI-1regulatesthetemporal/spatialcontrolofpericellularproteolysis,promotesepithelialplasticity,inhibits
capillary regression and facilitates stromal invasion. Deﬁning TGF-β1-initiated signaling events that cooperate with an activated
EGFR to impact the protease-protease inhibitor balance in the tumor microenvironment is critical to the development of novel
therapies for the clinical management of human cancers.
Copyright © 2009 Rohan Samarakoon et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Transition of a normal epithelial cell to an early malig-
nant phenotype often involves mutation of the p53 and
p21ras genes and progressive increases in autocrine TGF-
β1 expression [1–10]. Elevated TGF-β1 production, in fact,
typiﬁes advanced pathologies in both mouse and human
SCC [8, 10, 11]. Despite relatively high concentrations of
TGF-β in the immediate tumor microenvironment, some
malignant epithelial cells become refractory to TGF-β1-
initiated proliferative arrest likely due to reductions in
either TGF-βRII and/or SMAD4 levels as well as the
now recognized p21ras-dependent antagonism of TGF-β1-
mediated growth inhibition/apoptosis [10–13]. In certain
epithelial malignancies, moreover, resistance to TGF-β1-
mediated growth suppression is often coupled with EGFR
ampliﬁcation or dysregulated EGFR signaling, particularly
during the later stages of tumor development [14–19]. The
associated reprogramming of gene expression initiates and
perpetuates TGF-β1-induced cellular “plasticity” (usually
referred to as epithelial-to-mesenchymal transition or EMT)
which facilites tumor invasion and metastasis [8, 20–25].
MicroarrayoftheEMTtranscriptomeinseveralclinically
relevant model systems has provided insights into the spe-
ciﬁc repertoire of “plasticity” genes. Plasminogen activator
inhibitor type-1 (PAI-1; SERPINE1), the major physiologic
regulator of the pericellular plasmin-generating cascade, is
a prominent member of the subset of TGF-β1-induced,
EMT-associated genes in human malignant keratinocytes
[21, 26, 27]. In epithelial cells undergoing a mesenchymal-
like conversion in response to the E-cadherin transcriptional
repressors Snail, Slug or E47, PAI-1 upregulation appears
to be an essential characteristic of the plastic phenotype
[28]. The association between PAI-1 expression and tumor2 Journal of Oncology
“progression” has signiﬁcant clinical implications. Current
data suggest that this serine protease inhibitor maintains
an angiogenic “scaﬀold,” stabilizes nascent capillary vessel
structure, and facilitates tumor cell invasion through precise
control of the peritumor proteolytic microenvironment [29–
31]. Increased PAI-1 expression is, in fact, an early event in
the progression of epidermal SCC, often localizing to tumor
cellsandmyoﬁbroblastsattheinvasivefront[24,32–36]and,
most importantly, is a biomarker with signiﬁcant prognostic
value [37]. Indeed, two of the best-validated prognostic
indicators (level of evidence [LOE] = 1) in breast carcinoma
are the serine protease urokinase plasminogen activator
(uPA) and its endogenous inhibitor PAI-1 [38]. Certain
PAI-1 tumor thresholds predict both poor prognosis and
reduced disease-free survival in patients with breast, lung,
ovarian,andoralSCC[29,38]withtheexpressionamplitude
frequentlyassociatedwiththe4GpolymorphismatthePE1E
box motif in the PAI-1 promoter [37]. Identiﬁcation of PAI-
1 in tumor-proximal stromal myoﬁbroblasts, furthermore,
implies a more global involvement in modulating cellular
invasive potential [34–36] ,pe rh a p sa sam a tri c e ll u l a re ﬀector
of epithelial motility [39], invasion and the associated
angiogenic response [24, 30, 31, 40, 41].
Recent ﬁndings clearly implicate EGFR/MEK/rho-ROCK
signaling as required for PAI-1 expression in TGF-β1-
stimulated cells. E box motifs (CACGTG) in the PAI-1
PE1/PE2 promoter regions, moreover, are platforms for a
MAP kinase-directed upstream stimulatory factor (USF)
s u b t y p es w i t c h( U S F - 1 → USF-2) in response to growth
factor addition [42–44] suggesting that the EGFR/MEK/rho-
ROCK axis impacts PAI-1 expression through USF-
dependent transcriptional controls. The continued deﬁni-
tion of TGF-β1-activated pathways that inﬂuence expression
of this important target gene may lead to therapeutically
useful approaches to manage human cancer. This paper,
therefore, reviews data regarding the rapid transactivation of
the EGFR in TGF-β1-stimulated cells suggesting cooperativ-
ity between TGF-β1 and EGFR → MAP kinase pathways in
PAI-1 gene expression.
2. EGFRSignalingIsRequiredfor
TGF-β1-InducedPAI-1 Expression
TGF-β1mobilizes both SMAD-dependent and -independent
signaling [45] although the individual roles of speciﬁc cross-
pathway events on PAI-1 expression are not well under-
stood. Several recent studies demonstrated that TGF-β1-
inducedrapidEGFRtransactivationhighlightingcooperativ-
ity between TGF-β1 and EGFR signaling events in vascular,
epithelial, and endothelial cells. Indeed, PAI-1 induction
in response to TGF-β1 is signiﬁcantly attenuated by an
EGFR pharmacologic inhibitor (AG1478), by molecular
targeting of EGFR activity (i.e., by adenoviral delivery of
EGFRY721A kinase-dead constructs) and, more importantly,
by genetic ablation of the EGFR in mouse ﬁbroblasts
[43, 46, 47] with PAI-1 “rescue” evident in EGFR−/− cells
engineeredtoexpressanEGFRconstruct.TGF-β1treatment,
moreover, speciﬁcally increased EGFR phosphorylation at
the Y845 src-target residue; either mutation of this residue
(EGFRY845F) or transfection of a DN pp60c-src construct
completely blocked TGF-β1-dependent PAI-1 induction.
Similarly, TGF-β1 failed to stimulate PAI-1 expression in
cultured mouse embryonic ﬁbroblasts (MEFs) genetically
deﬁcient in three src family kinases (i.e., c-src,c - yes-, c-
fyn- null ﬁbroblasts; SYF−/−/−) compared to identically
stimulated wild-type SYF+/+/+ cells. PAI-1 synthesis was
restored in SYF−/−/− MEFs engineered to re-express a
wild-type pp60c-src [47] providing proof-of-principle for
involvement of this particular src kinase in the inductive
response. The highly speciﬁc src family kinase inhibitor
SU6656, morevover, eﬀectively blocked TGF-β1-initiated
increases in both pp60c-src and EGFR phosphorylation as
well as pp60c-src and EGFR activation (at the Y416 and Y845
residues, resp.). pEGFRY845 phosphorylation in response to
TGF-β1 was evident, furthermore, in wild type but not
SYF−/−/− ﬁbroblasts. The TGF-β1-dependent formation of
EGFR/pp60c-src complexes [46] and EGFRY845 phosphoryla-
tionandtheinhibition ofTGF-β1-(butnotPDGF-)induced
PAI-1 expression by the EGFRY845F mutant as well as a
DN-Src construct [47] collectively implicate EGFR/pp60c-src
interactions and, in particular, the EGFRY845 pp60c-src site in
thekinasedomainactivationloopinsignalpropagation[48].
The time course of TGF-β1-initiated SMAD2/3 activation, in
contrast, was similar in both wild type and SYF−/−/− MEFs
conﬁrming that, in the context of either EGFR or src family
kinase deﬁciency, SMAD2/3 activation occurs but is not
suﬃcient for PAI-1 induction. TGF-β1 stimulated ERK1/2
phosphorylation in EGFR+/+ but not in EGFR−/− cells
consistent with prior observations that TGF-β1-dependent
ERK1/2activationisdownstreamofEGFRsignaling[43,46].
EGFR−/− MEFs, however, are fully capable of responding to
exogenous TGF-β1 as SMAD2 was eﬀectively activated (i.e.,
phosphorylated) in both wild type and EGFR−/− ﬁbroblasts
[47].
3. The PAI-1 GeneIsa Model of
TGF-β1-InitiatedCooperative
EGFRSignaling
While TGF-β1 receptors phosphorylate SMADs downstream
of growth factor engagement, it appears that the Rho/ROCK
pathway modulates the duration of SMAD2/3 phospho-
rylation [47]. How Rho/ROCK impact TGF-β1-initiated
SMAD2/3 activation and subcellular localization [49, 50]i s
notknownbutthispathwaymayfunctiontoprovideeﬃcient
SMAD2/3 activation for extended periods. Alternatively,
Rho/ROCK signaling may be required to inhibit negative
regulation of SMAD2/3 function by inactivation of SMAD
phosphatases sustaining, thereby, SMAD2/3 transcriptional
actions (e.g., [51, 52]). TGF-β1-induced SMAD2 phospho-
rylation is not altered by EGFR blockade either pharma-
cologically (with AG1478), molecularly (by expression of
EGFRY721A or EGFRY845F), or by the genetic absence of EGFR
[47]. Clearly, while SMAD2/3 activation may be necessary it
is not suﬃcient for TGF-β1-stimulated PAI-1 expression in
the absence of EGFR signaling.Journal of Oncology 3
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Figure 1: Model for TGF-β1-induced PAI-1 expression. TGF-β1 activates two distinct signaling pathways to initiate PAI-1 transcription.
Rho/ROCK are required to maintain SMAD phosphorylation and ERK activation (through to be deﬁned mechanisms) while the pp60c-src-
activated EGFR (at the Y845 site) signals to MEK-ERK initiating ERK/USF interactions resulting in USF phosphorylation and a subtype
(USF-1 → USF-2) switch (e.g., [44]) at the PAI-1 PE1/PE2 E box sites. Collectively, these promoter-level events stimulate high level PAI-1
expression in response to TGF-βR occupancy. The actual mechanism underlying EGFR activation in response to TGF-β1 may involve direct
recruitment of src kinases to the EGFR or the processing/release of a membrane-anchored EGFR ligand (e.g., HB-EGF). Events associated
with TGF-β1 stimulation of the RhoA/ROCK pathway are similarly unclear. Rho/ROCK may regulate the activity and/or function of the
SMAD phosphatase PPM1A impacting, thereby, the duration of SMAD-dependent transcription of target genes such as PAI-1. (modiﬁed
from [47]).
It is apparent, therefore, that TGF-β1 stimulates PAI-1
expression through two distinct but cooperating pathways
that involve EGFR/pp60c-src → MEK/ERK signaling and
EGFR-independent, but Rho/ROCK-modulated, TGF-βR-
directed SMAD and ERK activation [47]. Interference with
any of the speciﬁc individual elements in this dual cas-
cade (EGFR/pp60c-src/MEK or Rho/p160ROCK) markedly
reduced, and in some cases, completely inhibited PAI-
1 expression. One model consistent with the available
data [24, 40, 43, 44, 47, 53] suggests that SMADs and
speciﬁc MAP kinase-targeted bHLH-LZ factors (such as
USF) occupy their separate binding motifs at the critical
TGF-β1-responsive PE2 region E box in the PAI-1 promoter
(Figure 1). Dominant-negative interference with USF DNA-
binding ability signiﬁcantly reduced TGF-β1-mediated PAI-
1 transcription[43, 44, 53]. Since MAP kinases regulate the
DNA-binding and transcriptional activites of USF [40, 43],
TGF-βR signaling through SMAD2/3 may actually cooperate
with EGFR/MEK-ERK-activated USF to attain high level
PAI-1 expression [40, 47]. SMADs are known to interact
with E box-binding HLH-LZ factors such as TFE3 at the PE2
site in the PAI-1 geneat least in one cell type [54]. There is
evidence, in fact, to suggest that such interacting complexes
impact PAI-1 gene control since USF occupancy of the PAI-1
PE2 region E box site, which is juxtaposed to three SMAD-
recognitionelements,modulatestranscriptioninresponseto
TGF-β1o rs e r u m[ 40, 43, 44, 53]. Current data indicate that
recruitment of this multicomponent complex likely requires
participation of the TGF-β1-stimulated EGFR→MEK/ERK
and Rho/ROCK pathways for the optimal response of the
P A I - 1g e n et oT G F - β1.
The mechanism of MAP kinase activation in TGF-
β1-stimulated cells is just becoming clear. Upon ligand
binding, the TGF-βRII undergoes autophosphorylation on
three tyrosines (Y259, Y336, Y424), while Y284 is a tar-
get site for src kinases [55]. TGF-βRI is also subject to
tyrosine phosphorylation postreceptor accupancy [56]. Such
phosphorylated tyrosine residues provide docking sites for
recruitment of Grb2/Shc/SOS complexes with subsequent
mobilization of the ras-raf-MEK-ERK cascade [46, 47, 55].
Although ERKs are prominently activated in response to
TGF-β1[ 40, 43], perhaps the JNK and p38 MAP kinase
pathways are better characterized targets of TGF-β1-initiated
signaling. TGF-β1 rapidly activates JNK through MKK4 and
p38 via MKK3/6 perhaps even in a cell type-speciﬁc fashion
contributingtothemechanisticcomplexityofpathwaycross-
talk. Each of these kinase systems, moreover, has been
implicated in a cell type-dependency of PAI-1 gene control
[40, 43, 55]. Should such pathways prove uniquely or, at
least, preferentially utilized in speciﬁc cellular lineages, they
may provide tumor type-speciﬁc targets for intervention
therapy.4 Journal of Oncology
4. EGFRasa PotentialTherapeutic Target for
Regulating PAI-1 Expression
Modulation of EGFR/HER1 signaling by speciﬁc receptor
function(kinasedomain) inhibitors orneutralizing antibod-
ies against speciﬁc EGFR1 ligands (e.g., HB-EGF antibodies)
can be an attractive therapeutic modality (particularly in
the context of neoplastic diseases associated with elevated
TGF-β1 levels). This strategy would likely impact not only
PAI-1 suppression but has the potential to regulate other
proinvasive target genes. There is, in fact, increasing evi-
dence that TGF-β1-induced connective tissue growth factor
and ﬁbronectin expression similarly involve EGFR/HER1
cooperative pathways (Samarakoon and Higgins, unpub-
lished data). Moreover, PAI-1 repression by EGFR signaling
blockade may also suppress tumor angiogenesis consistent
with the well-established role of PAI-1 as an inhibitor
of endothelial apoptosis and neovessel regression [40].
Combinatorial targeting of PAI-1 function using established
small molecule PAI-1 inhibitors and genetic-based PAI-
1 expression attenuation [40] coupled with disruption of
EGFR signaling (e.g., with cetuximab or erlotinib) may
impact, therefore, both cancer invasion and the associated
angiogenic response, particularly in the context of a TGF-β1-
rich tumor microenvironment.
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